Menu
 

Search abstracts


Systematic evaluation of efficacy and safety of noacs in atrial fibrillation therapy

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: ZENG, Yingtong (Guangdong General Hospital Guangdong Academy Institute)
  • Co-author(s): Yingtong Zeng: Pharmacy department, Guangdong General Hospital Guangdong Academy of Medical Sciences, Guangzhou, China
    Weihua Lai: Pharmacy department, Guangdong General Hospital Guangdong Academy of Medical Sciences, Guangzhou, China
    Jing Zhou: Pharmacy department, Guangdong General Hospital Guangdong Academy of Medical Sciences, Guangzhou, China
    Yi Yang: Pharmacy department, Guangdong General Hospital Guangdong Academy of Medical Sciences, Guangzhou, China
  • Abstract:

    Background

    Non-Vitamin K antagonist oral anticoagulants (NOACs) are now widely used in patients with non-valvular atrial fibrillation (AF)s. NOACs include dabigatran, apixaban,rivaroxaban and edoxaban.

    Methods

    The randomized controlled trials of NOACs versus warfarin in the treatment of atrial fibrillation,which had been published from the time of

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses